Table 1.

Participant demographics and baseline characteristics.^a

Characteristic	Evaluated population
Mean ±standard deviation or %	Teriflunomide (n = 524)	Ublituximab (n = 520)
Age, years	36.5 ± 9.4	35.3 ± 8.7
Sex, female, %	64.3	63.3
Region, %
US & Western Europe	9.0	8.7
Eastern Europe	91.0	91.3
Duration of MS since first symptoms, years	7.0 ± 6.0	7.4 ± 6.4
Time since diagnosis, years	4.7 ± 5.0	4.9 ± 5.3
Number of relapses in last 12 months	1.3 ± 0.7	1.3 ± 0.6
Number of relapses in last 24 months	1.9 ± 1.0	1.8 ± 1.0
Time since most recent relapse, months	6.3 ± 4.9	7.1 ± 8.6
EDSS score at screening	2.9 ± 1.2	2.9 ± 1.3
T2 lesion volume, mL	15.2 ± 16.7	15.2 ± 14.8
Number of T2 lesions	62.5 ± 39.6	64.8 ± 39.8
Participants free of Gd+ T1 lesions, %	53.4	51.7

^aParticipants included in NEDA-3 analyses.

EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; MS, multiple sclerosis; NEDA-3, 3-parameter no evidence of disease activity.